Cargando…

Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis

BACKGROUND: Despite the belief that heart failure therapies are not effective in transthyretin cardiac amyloidosis, data are limited. We tested the association of neurohormonal blockade use with survival. METHODS AND RESULTS: A total of 309 consecutive patients with transthyretin cardiac amyloidosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Richard K., Vasbinder, Alexi, Levy, Wayne C., Goyal, Parag, Griffin, Jan M., Leedy, Douglas J., Maurer, Mathew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075255/
https://www.ncbi.nlm.nih.gov/pubmed/34729989
http://dx.doi.org/10.1161/JAHA.121.022859
_version_ 1784701641318989824
author Cheng, Richard K.
Vasbinder, Alexi
Levy, Wayne C.
Goyal, Parag
Griffin, Jan M.
Leedy, Douglas J.
Maurer, Mathew S.
author_facet Cheng, Richard K.
Vasbinder, Alexi
Levy, Wayne C.
Goyal, Parag
Griffin, Jan M.
Leedy, Douglas J.
Maurer, Mathew S.
author_sort Cheng, Richard K.
collection PubMed
description BACKGROUND: Despite the belief that heart failure therapies are not effective in transthyretin cardiac amyloidosis, data are limited. We tested the association of neurohormonal blockade use with survival. METHODS AND RESULTS: A total of 309 consecutive patients with transthyretin cardiac amyloidosis were identified. Medication inventory was obtained at baseline and subsequent visits. Exposure included a neurohormonal blockade class (β‐blocker [βB], angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker, and mineralocorticoid antagonist) at baseline and subsequent visits. βB was modeled as baseline use, time‐varying use, and in an inverse probability treatment weighted model. Primary outcome was all‐cause mortality analyzed with adjusted Cox proportional hazards models. Continuing compared with stopping βB during follow‐up was tested. Mean age was 73.2 years, 84.1% were men, and 17.2% had atrial fibrillation/flutter at baseline. At the time of study entry, 49.8% were on βBs, 35.0% were on angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, and 23.9% were on mineralocorticoid antagonists. For the total cohort, there was a trend toward harm in the unadjusted model for baseline βB use, but this was neutral after adjustment. When βB use was analyzed as a time‐varying exposure, there was no association with mortality. βB discontinuation was associated with decreased mortality for the total cohort. Findings were consistent in inverse probability treatment weighted models. For angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker or mineralocorticoid antagonist use, there was no association with mortality after adjustment for the total cohort. CONCLUSIONS: There was no association of neurohormonal blockade use with survival in transthyretin cardiac amyloidosis. For the total cohort, deprescribing βB may be associated with improved survival. Additional studies are needed to confirm these findings.
format Online
Article
Text
id pubmed-9075255
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90752552022-05-10 Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis Cheng, Richard K. Vasbinder, Alexi Levy, Wayne C. Goyal, Parag Griffin, Jan M. Leedy, Douglas J. Maurer, Mathew S. J Am Heart Assoc Original Research BACKGROUND: Despite the belief that heart failure therapies are not effective in transthyretin cardiac amyloidosis, data are limited. We tested the association of neurohormonal blockade use with survival. METHODS AND RESULTS: A total of 309 consecutive patients with transthyretin cardiac amyloidosis were identified. Medication inventory was obtained at baseline and subsequent visits. Exposure included a neurohormonal blockade class (β‐blocker [βB], angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker, and mineralocorticoid antagonist) at baseline and subsequent visits. βB was modeled as baseline use, time‐varying use, and in an inverse probability treatment weighted model. Primary outcome was all‐cause mortality analyzed with adjusted Cox proportional hazards models. Continuing compared with stopping βB during follow‐up was tested. Mean age was 73.2 years, 84.1% were men, and 17.2% had atrial fibrillation/flutter at baseline. At the time of study entry, 49.8% were on βBs, 35.0% were on angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, and 23.9% were on mineralocorticoid antagonists. For the total cohort, there was a trend toward harm in the unadjusted model for baseline βB use, but this was neutral after adjustment. When βB use was analyzed as a time‐varying exposure, there was no association with mortality. βB discontinuation was associated with decreased mortality for the total cohort. Findings were consistent in inverse probability treatment weighted models. For angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker or mineralocorticoid antagonist use, there was no association with mortality after adjustment for the total cohort. CONCLUSIONS: There was no association of neurohormonal blockade use with survival in transthyretin cardiac amyloidosis. For the total cohort, deprescribing βB may be associated with improved survival. Additional studies are needed to confirm these findings. John Wiley and Sons Inc. 2021-11-03 /pmc/articles/PMC9075255/ /pubmed/34729989 http://dx.doi.org/10.1161/JAHA.121.022859 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Cheng, Richard K.
Vasbinder, Alexi
Levy, Wayne C.
Goyal, Parag
Griffin, Jan M.
Leedy, Douglas J.
Maurer, Mathew S.
Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis
title Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis
title_full Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis
title_fullStr Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis
title_full_unstemmed Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis
title_short Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis
title_sort lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075255/
https://www.ncbi.nlm.nih.gov/pubmed/34729989
http://dx.doi.org/10.1161/JAHA.121.022859
work_keys_str_mv AT chengrichardk lackofassociationbetweenneurohormonalblockadeandsurvivalintransthyretincardiacamyloidosis
AT vasbinderalexi lackofassociationbetweenneurohormonalblockadeandsurvivalintransthyretincardiacamyloidosis
AT levywaynec lackofassociationbetweenneurohormonalblockadeandsurvivalintransthyretincardiacamyloidosis
AT goyalparag lackofassociationbetweenneurohormonalblockadeandsurvivalintransthyretincardiacamyloidosis
AT griffinjanm lackofassociationbetweenneurohormonalblockadeandsurvivalintransthyretincardiacamyloidosis
AT leedydouglasj lackofassociationbetweenneurohormonalblockadeandsurvivalintransthyretincardiacamyloidosis
AT maurermathews lackofassociationbetweenneurohormonalblockadeandsurvivalintransthyretincardiacamyloidosis